ArticleCancer reports (Hoboken, N.J.)2026
Assessing Delay Patterns in Diagnosis and Care Among Breast Cancer Patients in Ethiopia.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Ethiopia, breast cancer patients often present with advanced-stage disease, leading to high mortality. This study aimed to quantify diagnostic and treatment intervals and identify their association with stage at presentation.
aimThe aim of this study is to determine the role of specific types of delay on the stage of disease presentation for breast cancer. METHODS AND
resultsA multicenter cross-sectional study was conducted at Ethiopia's two largest tertiary oncology centers. Data from 205 histologically confirmed breast cancer patients were analyzed using multivariable logistic regression and random forest machine learning to evaluate the impact of various time intervals on disease stage. The median total delay was 5.05 months, with more than half of patients exceeding a six-month interval from symptom onset to treatment initiation. Primary delay (patient interval) was the dominant contributor, accounting for over 77% of the total variance in delay. Total delay > 6 months was independently associated with a 4.26-fold higher odds of advanced-stage (Stage III/IV) presentation (AOR 4.26, 95% CI: 2.07-8.77, p < 0.001). Lack of awareness was the primary reason for delay (77.8%), while complementary medicine use and absence of pain were not significantly associated with prolonged total delay.
conclusionThe majority of delays occur during the pre-clinical phase. Reducing primary delay through targeted community awareness and improved symptom recognition is critical to achieving earlier diagnosis and reducing breast cancer mortality in Ethiopia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.